UPCC 44825 A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FR-high and AZD5335 Versus Investigators Choice Chemotherapy in FR-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Enrolling By Invitation
99 years or below
All
Phase N/A

Brief description of study

This research study is designed to learn more about the safety and effectiveness of AZD5335, given to individuals who have been diagnosed with platinum-resistant ovarian cancer, by comparing AZD5335 to standard of care therapies.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 02 Oct 2026. Study ID: 26-6235
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator